Ophthalmic Suspension Market-Rising Prevalence of Eye Diseases & Demand for New Diagnostic Techniques Accelerate the Growth of the Market

Ophthalmic Suspension market-Overview

The Ophthalmic Suspension Market is anticipated to grow at an 8.3% CAGR from 2022 to 2030, reaching a value of USD 5,172.3 million by 2030.

Ophthalmic suspensions are used to treat eye infections and various other eye diseases. For better results, they are used in a combination of antibiotics and corticosteroids. There are various bacterial eye infections such as conjunctivitis are treated by ophthalmic suspension.  

The market is driven by rising prevalence of eye diseases across the globe, increasing geriatric population with eye diseases such as diabetic retinopathy, and growing number of bacterial infection in children. As per to WHO (2014), glaucoma is the second major cause of blindness in the world which will increase the market growth. It also stated that cataract is responsible for 51% of world blindness and is one of the important cause of vision of loss in developing countries. Additionally increasing awareness about effect of diabetes on the eye and preventive measures also fuels the growth of the market.

Key players in the Ophthalmic Suspension market                                                               

Novartis AG (Alcon Laboratories, Inc.), ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant, Bayer AG, and Genentech, Inc.

Key developments

Strategic approaches adopted help the major players to sustain their growth in the market and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.

Alcon Laboratories, Inc.

Alcon Laboratories, Inc. offers various product for eye care such as contact lenses, dry eye product, allergy/redness relief, eye wash, eye vitamin, surgical products, vision accessories, safety and industrial cleaning products, and diagnostics.

• November, 2017: Alcon Laboratories, Inc. introduced the newly optimized UltraSert delivery system pre-loaded with the AcrySof IQ aspheric monofocal intraocular lens (IOL) for people undergoing cataract surgery at the 2017 American Academy of Ophthalmology (AAO) annual meeting.


• October, 2017: Alcon Laboratories, Inc. introduced Clareon the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS).


• October, 2017: Alcon announced the US launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology (AAO).


• May, 2017: Alcon launched AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with ACTIVEFOCUS optical design at the American Society of Cataract and Refractive Surgery (ASCRS) 2017 annual meeting.


• September, 2016: Alcon launched the NGENUITY 3D Visualization System, a platform for Digitally Assisted Vitreoretinal Surgery (DAVS), in collaboration with TrueVision 3D Surgical. The system is designed to enhance visualization of the back of the eye for improved surgeon experience. TrueVision 3D Surgical is a California-based company specializing in digital 3D visualization and guidance for microsurgery.

Explore In-depth Details: Ophthalmic Suspension Market Research Report

Bausch & Lomb Incorporated.:

• November, 2017: Bausch & Lomb Incorporated. launched expanded parameters of Bausch + Lomb ULTRA for Astigmatism contact lenses.


• October, 2017: Bausch & Lomb Incorporated. announced the introduction of the enVista MX60E with StableFlex technology. This lens is the next generation of the company`s hydrophobic acrylic lens, which provides improved material properties to enhance optic recovery following delivery.


• August, 2017: Bausch & Lomb Incorporated. announced the U.S. launch of the Stellaris Elite vision enhancement system for retina surgery, which integrates advanced retina capabilities into the next-generation surgical platform. This new system features multiple advancements as well as the ability to seamlessly integrate future technologies, such as the Vitesse hypersonic vitrectomy system, which will be exclusive to Stellaris Elite.


• July, 2017: Bausch & Lomb Incorporated. announced the U.S. launch of the FortifEYE capsular tension ring (CTR).

Global Ophthalmic Suspension Market

North America dominates the Americas ophthalmic suspension market. North America is further segmented into the U.S. and Canada. The U.S. holds the major share of the market owing to rising prevalence of eye diseases, increasing awareness about diagnosis and treatment of eye diseases, and the government support for research & development. South America is still a developing region in terms of the infrastructure and technology. 

According to the National Eye Institute, 2014 (US), 2.9 million Americans have low vision and an estimated 5 million Americans will have low vision by 2030 which will drive the market growth. Moreover, 2.1 million Americans have advanced AMD (Age-related Macular Degeneration), and is estimated to have 3.7 million by 2030. Furthermore, 7.7 million Americans have diabetic retinopathy and is estimated 11.3 million will have diabetic retinopathy by 2030.  The American healthcare industry has been experiencing positive trend owing to strong economic conditions, and development of innovative healthcare solutions in ophthalmology.